Evidence map›Paper›PMID 25229241›Full record

ArticlePloS one2014

Activation of c-Myc and Cyclin D1 by JCV T-Antigen and β-catenin in colon cancer.

Michael J Ripple, Amanda Parker Struckhoff, Jimena Trillo-Tinoco, Li Li, David A Margolin, Robin McGoey, Luis Del Valle

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Function ofOncology letters · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michael J RippleStanley S. Scott Cancer Center, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America; Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Amanda Parker StruckhoffStanley S. Scott Cancer Center, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Jimena Trillo-TinocoStanley S. Scott Cancer Center, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Li LiInstitute for Translational Research, Ochsner Clinic Foundation, New Orleans, Louisiana, United States of America.
David A MargolinDepartment of Colorectal Surgery, Ochsner Clinic Foundation, New Orleans, Louisiana, United States of America.
Robin McGoeyDepartment of Pathology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Luis Del ValleStanley S. Scott Cancer Center, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America; Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Louisiana State University Health Sciences Center New Orleans · USOchsner Medical Center · US

Funding

TUMOR MICROENVIRONMENT AND B CELL LYMPHOMASP20RR021970 · NCRR · LSU HEALTH SCIENCES CENTER · PI ESTRADA, JOHN J. · 2005 to 2011
$14.1M
Translational Genomics CoreP30GM114732 · NIGMS · LSU HEALTH SCIENCES CENTER · PI OCHOA, AUGUSTO C. · 2015 to 2019
$5.2M
NCRR NIH HHS P20 RR021970NIGMS NIH HHS P30 GM114732
6 · The paper itself

Abstract

During the last decade, mounting evidence has implicated the human neurotropic virus JC virus in the pathology of colon cancer. However, the mechanisms of JC virus-mediated oncogenesis are still not fully determined. One candidate to mediate these effects is the viral early transcriptional product T-Antigen, which has the ability to inactivate cell cycle regulatory proteins such as p53. In medulloblastomas, T-Antigen has been shown to bind the Wnt signaling pathway protein β-catenin; however, the effects of this interaction on downstream cell cycle regulatory proteins remain unknown. In light of these observations, we investigated the association of T-Antigen and nuclear β-catenin in colon cancer cases and the effects of this complex in the activation of the transcription and cell cycle regulators c-Myc and Cyclin D1 in vitro. Gene amplification demonstrated the presence of viral sequences in 82.4% of cases and we detected expression of T-Antigen in 64.6% of cases by immunohistochemistry. Further, we found that T-Antigen and β-catenin co-localized in the nuclei of tumor cells and we confirmed the physical binding between these two proteins in vitro. The nuclear presence of T-Antigen and β-catenin resulted in the significant enhancement of TCF-dependent promoter activity and activation of the β-catenin downstream targets, c-Myc and Cyclin D1. These observations provide further evidence for a role of JCV T-Antigen in the dysregulation of the Wnt signaling pathway and in the pathogenesis of colon cancer.

Indexed as

Antigens, Viral, Tumorbeta CateninColonic NeoplasmsCyclin D1HCT116 CellsHumansIn Vitro TechniquesJC VirusProto-Oncogene Proteins c-mycAntigens, Viral, Tumorbeta CateninCyclin D1Proto-Oncogene Proteins c-myc

Identifiers

PMID25229241
PMCPMC4167695
OpenAlexW2025851086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.